Search
Descriptor English: Immunotherapy, Adoptive
Descriptor Spanish: Inmunoterapia Adoptiva
Descriptor Portuguese: Imunoterapia Adotiva
Descriptor French: Immunothérapie adoptive
Entry term(s): Adoptive Cellular Immunotherapies
Adoptive Cellular Immunotherapy
Adoptive Immunotherapies
Adoptive Immunotherapy
CAR T Cell Therapy
CAR T-Cell Therapies
CAR T-Cell Therapy
Cellular Immunotherapies, Adoptive
Cellular Immunotherapy, Adoptive
Chimeric Antigen Receptor Therapy
Immunotherapies, Adoptive
Immunotherapies, Adoptive Cellular
Immunotherapy, Adoptive Cellular
T-Cell Therapies, CAR
T-Cell Therapy, CAR
Therapies, CAR T-Cell
Therapy, CAR T-Cell
Tree number(s): E02.095.465.425.400.330.050.400
E05.478.550.520.050.400
RDF Unique Identifier: https://id.nlm.nih.gov/mesh/D016219
Scope note: Form of adoptive transfer where cells with antitumor activity are transferred to the tumor-bearing host in order to mediate tumor regression. The lymphoid cells commonly used are lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TIL). This is usually considered a form of passive immunotherapy. (From DeVita, et al., Cancer, 1993, pp.305-7, 314)
Annotation: for CAR T-Cell Therapy, coordinate with RECEPTORS, CHIMERIC ANTIGEN
Allowable Qualifiers: AE adverse effects
CL classification
EC economics
ES ethics
HI history
IS instrumentation
LJ legislation & jurisprudence
MO mortality
MT methods
NU nursing
PX psychology
SN statistics & numerical data
ST standards
TD trends
VE veterinary
Previous Indexing: Immunization, Passive (1983-1990)
History Note: 1991
Entry Version: IMMUNOTHER ADOPTIVE
Related: Receptors, Chimeric Antigen MeSH
DeCS ID: 28992
Unique ID: D016219
Documents indexed in the Virtual Health Library (VHL): Click here to access the VHL documents
Date Established: 1991/01/01
Date of Entry: 1990/06/06
Revision Date: 2018/07/02
Immunotherapy, Adoptive - Preferred
Concept UI M0024767
Scope note Form of adoptive transfer where cells with antitumor activity are transferred to the tumor-bearing host in order to mediate tumor regression. The lymphoid cells commonly used are lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TIL). This is usually considered a form of passive immunotherapy. (From DeVita, et al., Cancer, 1993, pp.305-7, 314)
Preferred term Immunotherapy, Adoptive
Entry term(s) Adoptive Cellular Immunotherapies
Adoptive Cellular Immunotherapy
Adoptive Immunotherapies
Adoptive Immunotherapy
Cellular Immunotherapies, Adoptive
Cellular Immunotherapy, Adoptive
Immunotherapies, Adoptive
Immunotherapies, Adoptive Cellular
Immunotherapy, Adoptive Cellular
Chimeric Antigen Receptor Therapy - Narrower
Concept UI M000639995
Preferred term Chimeric Antigen Receptor Therapy
Entry term(s) CAR T Cell Therapy
CAR T-Cell Therapies
CAR T-Cell Therapy
T-Cell Therapies, CAR
T-Cell Therapy, CAR
Therapies, CAR T-Cell
Therapy, CAR T-Cell



We want your feedback on the new DeCS / MeSH website

We invite you to complete a survey that will take no more than 3 minutes.


Go to survey